SAHPRA’s position on GLP1 and GIP-GLP1 products that are compounded, substandard and falsified

News Healthcare & Pharma Guidance

Date: 8th Nov, 2024 Source: South African Health Products Regulatory Authority (SAHPRA) Country: South Africa Original Source

Brief

On 08/11/2024, the South African Health Products Regulatory Authority (SAHPRA) issued an update regarding SAHPRA's position on GLP1 and GIP-GLP1 products that are compounded, substandard and falsified. SAHPRA is concerned about the proliferation of falsified and unauthorised versions of semaglutide and tirzapetide being sold to the public, posing a health risk due to their unknown safety and quality.

This content is restricted.

Highlights content goes here...

This content is restricted.

South African Health Products Regulatory Authority (SAHPRA)

RADA.AI

Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?

Suggested

SAHPRA’s position on GLP1 and GIP-GLP1 products that are compounded, substandard and falsified

Brief

South African Health Products Regulatory Authority (SAHPRA)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.

SAHPRA’s position on GLP1 and GIP-GLP1 products that are compounded, substandard and falsified

Brief

South African Health Products Regulatory Authority (SAHPRA)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify OTP

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.